Skip to content

OWP Pharmaceuticals Announces IND Approval and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Topiramate for the Treatment of Epilepsy and Migraine

Share this press release:

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved.
Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use